Member Info for mol42

@ 19.18

though @19.25 not to be ignored

mol

That is actually one of your most interesting and commercially relevant posts ever on this board - at least in terms that most here can understand

nevermind whatever other reasons you have for posting

thank goodness for turkeys

mol

Don't disagree re regulation - but that's aim - i think i admin costs are too much and our ceo salary is and has been over the top from the start - only now are most of the supporters here catching up - though i don't think it is completely "back a blag "- albeit i understand from where you may think that

mol

I would argue that many have potential ideas /research that never even reach a hint of a commercial product nevermind a commercial success and go bust - some sooner than others

we at least have two organic commercial products -albeit whether a commercial success to cover our costs and produce a profit - is still unknown at this stage

mol

And of course feeding

mol

Well why not

the turkey illusion

Turkey illusion is a cognitive bias describing the surprise resulting from a break in a trend, if one does not know the causes or the framework conditions for this trend. The concept was first introduced by Bertrand Russell to illustrate a problem with inductive reasoning.

Relevant disciplines for uncovering such biases include psychology and behavioral economics.

The story

In a variation from Russell's original, a turkey designated for Thanksgiving is fed and cared for every day until it is slaughtered. With each feeding, its certainty or confidence that nothing will happen to it increases, based on past experience. From the turkey's point of view, the certainty that it will be fed and cared for again the next day is greatest on the night before it dies, of all days. Nevertheless, it is slaughtered that day, by the very person who cared for it.

The story appears in Bertrand Russell's 1912 The Problems of Philosophy as relating to a chicken:

The man who has fed the chicken every day throughout its life at last wrings its neck instead, showing that more refined views as to the uniformity of nature would have been useful to the chicken.

The slaughter comes as a complete surprise to the turkey, who - in anthropomorphic formulation - "only extrapolates a trend" and "does not recognize the impending trend break". To recognize this trend break, the turkey would have had to find out the causes of the trend. By doing so, it would have known about the motivational state of the human who feeds it every day. In order to "think outside the box" and leave known or familiar thought patterns, creativity and the ability to change perspectives are necessary. This was not possible for the turkey due to insufficient information.

I would argue that no what other information was available to said turkey it wouldn't have made any difference to either its understanding or outcome

mind back to shares and trends.......

mol

I suggest you actually read the company's annual report!

and obviously so should the Wall Street Journal!

https://www.skinbiotherapeutics.com/wp-content/uploads/2024/12/269662-SkinBio-Therapeutics-AR-WEB75.pdf

and next time please quote your source - as it would save me a lot of time - lol

mol

I'll keep it short

Your figure £3.4m for intangibles is wrong and the increase in carrying value during 2024 has nowt to do with the croda deal

Simple enough i would have thought

anyway

The company has been capitalising some development and IP expenditure over the years as an intangible asset and is reviewed on an annual basis for any impairment value - to date none has been idenified and the auditor to date has agreed - and apart from beginning to (part) amortise expenditure re axisbiotix

the rest is carried forward until commercialisation begins - hopefully further amortisation will occur in the 2025 financial statements due to skinbiotix!

mol

Actually

Intangible assets

The Group had capitalised intangible assets amounting to £1,388,959 (2023:£700,331). During the year, the Group and Company capitalised a further

£169,996 (2023: £75,483) relating to intellectual property costs and the Group also acquired £577,000 and £25,000 of Customer relationship and Brands,

respectively from the Dermatonics acquisition. The intellectual property costs are not yet being amortised as the products are in development stage except

for AxisBiotix Limited where amortisation has started because of the start of its selling activities.

The Directors have assessed whether the costs meet the criteria for capitalisation and whether there are any indicators of impairment.

The risk is that the costs may not qualify for capitalisation or technological advancements may render the market value of the capitalised costs below its

carrying value.

whilst USA here's an explanation re Customer Relationships and why it may be capitalised

https://viewpoint.pwc.com/dt/us/en/pwc/accounting_guides/business_combination/business_combination__28_US/chapter_4_intangible_US/43_types_of_identifi_US.html#pwc-topic.dita_c3cb64e1-f048-4bfd-b5c6-006f34cc0210

there is probably a uk equivalent but i haven't searched for one - anyway obviously capitalising and not writing off immediately gives a lesser loss

if it was me i'd have written off straight away - loss is big enough anyway - mind suppose they could claim loss on 2024 not much more than 2023 ie only c30k increase to (£2,875,990) at june 2024

someone is incorrectly adding the capitalised goodwill on dermatonics acquistion to the intangibles

nevermind

roll on the next big jump to support a further spurious argument

In 2024 SBTX increased their intangible assts from 700K to 3.4M (which is a massive rise) - I'm guessing that is mainly due to the CRODA deal...... If that is so, it appears that SBTX must have originally expected to make £500K a year out of Zenakine Tech...

mol

As we aren't listed on same - mind whether typical - i would suggest even worse

anyway re close period

pbx admission document

https://probiotixhealth-ir.com/docs/probiotixhealthlibraries/archive/admission-document.pdf

The Company has adopted a share dealing code for dealings in securities of the Company by the Directors and Persons Discharging Managerial responsibility which is appropriate for a company whose shares are traded on the AQSE Growth Market. This will constitute the Company’s share dealing policy for the

purpose of compliance with UK Legislation including the Market Abuse Regulation. It should be noted that the insider dealing legislation set out in the UK Criminal Justice Act 1993, as well as provisions relating to market abuse, will apply to the Company and dealings in Ordinary Shares

now to aqse growth market

https://www.aquis.eu/stock-exchange/rules-and-regulations/document-library

don't think aquis growth exchange defines same ie close period - you can search pdf

see 4

https://aqx-web-prod-s3-public-read.s3.eu-west-2.amazonaws.com/Access_Rulebook_v1_2_April_2023_3936b48356.pdf

An issuer must comply with:

(1) the Market Abuse Regulation, as applied to an issuer of securities admitted to an SME Growth Market;

(2) Chapter 2 of the DTR regarding the disclosure and control of inside information by issuers; and

(3) Chapter 3 of the DTR regarding transactions by persons discharging managerial responsibility and persons closely

associated with them.

mind follow the undernoted if you can

https://www.handbook.fca.org.uk/handbook/DTR.pdf

and our company has no immediate intention of moving to any other exchange according to Steen

mind he has been given further power to issue shares without prior offering to existing holders under res 7

the allotment (otherwise than pursuant to sub‐paragraph (a) above) of equity securities up to an aggregate nominal value

of £7,908.33 being 10% of the current issued share capital.

mol

I’m also not aware of any other mention since May

mol

Steen mentioned at end of imc presentation on the 29th when they also bought as noted in Rns 30th

mol

And

https://www.amazon.de/-/en/SymbioLife-Cholesterol-Control-Tablets-Lactobacillus/dp/B0CZTGMVTL

mol

Though bear in mind this

In the six months to 30 June 2024, OPTI’s sales fell 21 per cent. to £276,000. (The Independent Directors believe that at least 20 per cent. of OPTI’s sales relate to online sales of the CholBiome® brand containing ProBiotix’s LPLDL®, which is sold by OPTI under a licensing agreement with the Company. This agreement

is currently terminable by ProBiotix on giving 6 months’ notice.)

from the defence last year

https://probiotixhealth-ir.com/docs/probiotixhealthlibraries/archive/circulars/probiotix-circular.pdf

albeit the agreement is still in place at the moment - though notice may have been given - i doubt same with the recent agm and opti voting for all the resolutions mind

just doodling this evening

mol

Unfortunately

that was under

https://optibiotix.com/probiotix-health-launches-cholbiomech-at-vitafoods-europe/

and

https://probiotixhealth.com/wp-content/uploads/2023/10/233081-opti-cholbiome-ch-leaflet-update-23-v2-proof.pdf

and here

https://probiotixhealth.com/probiotix-health-signs-partner-agreement-with-symbiopharm/

but doesn't seem to have made its way to here

https://probiotixhealth.com/products/

mol

Whilst i haven't purchased same

https://www.openpr.com/news/4100257/2025-2034-phytosterols-market-outlook-key-drivers-emerging

nice to be at the forefront of summary

What Are the Key Trends Driving Phytosterols Market Growth?

In the phytosterols market, product innovation is becoming a significant trend. Key players in the market are prioritizing the development of new products and solutions to maintain their market standing. For instance, in May 2023, ProBiotix Health PLC, a British life sciences firm, introduced CholBiome CH, a revolutionary dual-action bi-layer tablet designed to lower cholesterol. The two primary ingredients of the tablet are Lactobacillus plantarum LPLDL and plant sterols/stanols (PSS), which together facilitate the objective of the dual-action cholesterol-reducing formula to reduce both internal and dietary cholesterol levels. In this innovative allergen- and GMO-free product, the award-winning component LPLDL acts on the internal cholesterol, generating enzymes that degrade bile salts. This prompts the liver to purge cholesterol from the blood, maintaining necessary levels and ensuring the bile salt pool within the body stays healthy.

What Are the Key Growth Drivers Fueling the Phytosterols Market Expansion?

The surge in cardiovascular disease cases has been identified as a notable factor boosting the growth of the phytosterols market. Cardiovascular disease, an umbrella term for various conditions affecting the heart and blood vessels, includes ailments like coronary heart disease, stroke, peripheral arterial disease, aortic disease, among others. Phytosterols or plant sterols have an essential function in mitigating cholesterol absorption by attaching to micelles which in turn, reduces cholesterol levels. Regular intake of phytosterols is linked to a reduction of 8% to 10% in LDL cholesterol levels. For clarity, in September 2024, the British Heart Foundation, a cardiovascular research organization based in the UK, highlighted that around 7.6 million people in the UK struggle with heart and circulatory diseases. Comprehensive statistics show that about 4 million males and 3.6 million females are dealing with these conditions. These conditions account for nearly 27% of all deaths in the United Kingdom, equating to over 170,000 deaths per year or approximately 480 deaths each day; this translates to one death every three minutes. Therefore, the surge in cardiovascular disease prevalence is fuelling the expansion of the phytosterols market.

mol

It is the vehicle through which the Danish nationals are paid

mol

Steen is also Chairman here

https://cambiotics.com/#team

mol

Probiotix Health Denmark ApS

Accounts to 31 Dec 2024

https://lasso.dk/api/company/report?id=47772834/amNsb3VkczovLzAzLzliLzRiLzU1Lzk3LzE0MGItNDM1My04NDJjLThlZjdlNjBiZDljNA.pdf

mol

Available within

https://probiotixhealth.com/a-new-era-in-menopause-health-its-time-for-a-real-change/

I was just trying to shortcut same with youtube link

mol

mol